Top-line data from all patients on the pri­ma­ry end­point of Kiadis Pharma’s Phase II tri­al with ATIR101TM select­ed for oral pre­sen­ta­tion at 42nd Annual Meeting of the European Society for Blood and Marrow Transplantation

~ Additional ATIR101TM data also select­ed for three poster pre­sen­ta­tions at EBMT ~

Amsterdam, The Netherlands, March 1, 2016, – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clin­i­cal stage bio­phar­ma­ceu­ti­cal com­pa­ny devel­op­ing inno­v­a­tive T-cell immunother­a­py treat­ments for blood can­cers and inher­it­ed blood dis­or­ders, today announces that key data from the Company’s ongo­ing sin­gle-dose Phase II clin­i­cal tri­al (NCT01794299/EudraCT 2012-004461- 41) with its lead prod­uct ATIR101TM has been select­ed for an oral pre­sen­ta­tion to dis­cuss the top-line data at the 42nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) on April 3-6, 2016 in Valencia, Spain. Three abstracts on addi­tion­al ATIR101TM data and the ATIR101TM devel­op­ment pro­gram have also been accept­ed for poster pre­sen­ta­tions at EBMT.
The oral pre­sen­ta­tion enti­tled ‘Donor lym­pho­cytes deplet­ed of allore­ac­tive T-cells (ATIR101) improve over­all sur­vival and reduce trans­plant relat­ed mor­tal­i­ty in a T-cell deplet­ed hap­loiden­ti­cal HSCT: Results from a Phase 2 Trial in patients with AML and ALL’ will be deliv­ered in Room B6 on Monday April 4, 2016 at 16:05 CET by Dr. Denis-Claude Roy, Professor of Medicine at the University of Montreal and prin­ci­pal inves­ti­ga­tor for the study.
The pre­sen­ta­tion will include the full dataset on the pri­ma­ry end­point of the study (Transplant Related Mortality at six months post trans­plan­ta­tion) which will also be put into per­spec­tive with oth­er cur­rent approach­es in the lit­er­a­ture for patients lack­ing a ful­ly matched donor, such as the Baltimore approach using post-trans­plant cyclophos­phamide.

Oral and poster pre­sen­ta­tions at EBMT:

Oral Presentation

Monday April 4, 2016 at 16:05 CET (Room B6)
Title: Donor lym­pho­cytes deplet­ed of allore­ac­tive T-cells (ATIR101) improve over­all sur­vival and reduce trans­plant relat­ed mor­tal­i­ty in a T-cell deplet­ed hap­loiden­ti­cal HSCT: Results from a Phase 2 Trial in patients with AML and ALL.
Presenting author: Denis-Claude Roy

Poster Presentations

Monday April 4, 2016 from 17:15-19:00 CET, Poster Area
– P020: Title: Leukemia-asso­ci­at­ed anti­gen reac­tive T-cells in ATIR101, a recip­i­ent-spe­cif­ic
allode­plet­ed T-cell prod­uct facil­i­tat­ing hap­loiden­ti­cal HSCT.
Presenting author: Jurjen Velthuis

Tuesday April 5, 2016 from 17:15-19:00 CET, Poster Area
– P442: Title: Effect of graft source on safe­ty and effi­ca­cy in patients under­go­ing
hematopoi­et­ic stem cell trans­plan­ta­tion.
Presenting author: Stephan Mielke

– P462: Title: An explorato­ry, open-label, mul­ti­cen­ter study to eval­u­ate safe­ty and effi­ca­cy of a two-dose reg­i­men of ATIR101 in patients with a hema­to­log­ic malig­nan­cy, who received a CD34-select­ed hematopoi­et­ic stem cell trans­plan­ta­tion from a hap­loiden­ti­cal donor.
Presenting author: Stephan Mielke

Full abstracts will be made avail­able on the EBMT web­site (http://www.ebmt2016.org/abstracts.html) but data pre­sent­ed dur­ing the oral pre­sen­ta­tion will con­tain addi­tion­al data that was not yet avail­able at the time of abstract sub­mis­sion.

Leave a Reply

Your email address will not be published. Required fields are marked *